Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/23/2023 | $7.00 | Outperform | Robert W. Baird |
9/7/2022 | $7.00 | Overweight | CapitalOne |
12/22/2021 | $21.00 → $24.00 | Buy | HC Wainwright & Co. |
11/22/2021 | $19.00 → $21.00 | Buy | HC Wainwright & Co. |
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G - CHIMERIX INC (0001117480) (Subject)
Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year.
https://twitter.com/DrTedros/status/1778423967105139108
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00
CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously
8-K - CHIMERIX INC (0001117480) (Filer)
10-Q - CHIMERIX INC (0001117480) (Filer)
8-K - CHIMERIX INC (0001117480) (Filer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo
DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. "We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization," said Mike Andriole, Chief Executive Officer of Chimerix. "Tom's in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 6580777. A live audio webcast of the call will also be availab
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2024 and provided an operational
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming presentations at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, which will be held in Houston, TX from November 21 – 24, 2024. "We are excited to provide an updated assessment of objective response to dordaviprone previously reported in the blinded independent central review (BICR) cohort1 in recurrent H3 K27M-mutant diffuse midline glioma using Response Assessment in Neuro-Oncology (RANO) 2.02, the most recently established crit
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 6580777. A live audio webcast of the call will also be availab